tiprankstipranks
Advertisement
Advertisement

TBPH Stock Latest News

Theravance Biopharma: Solid 1Q26 Execution, Cost Cuts, and YUPELRI Momentum Drive Buy Rating and Price Target Increase to $19
RatingsTheravance Biopharma: Solid 1Q26 Execution, Cost Cuts, and YUPELRI Momentum Drive Buy Rating and Price Target Increase to $19
7d ago
TBPH
Theravance: Hold Rating Reiterated as Restructuring Progress and Cash Flow Visibility Support Unchanged $15 Price Target
PremiumRatings
Theravance: Hold Rating Reiterated as Restructuring Progress and Cash Flow Visibility Support Unchanged $15 Price Target
27d ago
TBPH
Theravance Biopharma reports Q1 EPS (10c) vs. (17c) last year
PremiumThe Fly
Theravance Biopharma reports Q1 EPS (10c) vs. (17c) last year
27d ago
TBPH
TBPH Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
TBPH Upcoming Earnings Report: What to Expect?
1M ago
TBPH
Theravance Biopharma price target raised to $17 from $14 at B. Riley
PremiumThe Fly
Theravance Biopharma price target raised to $17 from $14 at B. Riley
2M ago
MNKD
TBPH
Theravance Secures Long-Term YUPELRI Patent Litigation Settlement
PremiumCompany AnnouncementsTheravance Secures Long-Term YUPELRI Patent Litigation Settlement
2M ago
8K
TBPH
Theravance Biopharma price target raised to $15 from $13 at TD Cowen
Premium
The Fly
Theravance Biopharma price target raised to $15 from $13 at TD Cowen
2M ago
TBPH
Theravance Biopharma: Post‑CYPRESS Restructuring Leaves Limited Upside and Justifies Neutral Stance
Premium
Ratings
Theravance Biopharma: Post‑CYPRESS Restructuring Leaves Limited Upside and Justifies Neutral Stance
2M ago
TBPH
Theravance Biopharma reports Q4 EPS $1.15, consensus $1.10
PremiumThe Fly
Theravance Biopharma reports Q4 EPS $1.15, consensus $1.10
3M ago
TBPH
Theravance Biopharma options imply 3.2% move in share price post-earnings
PremiumThe Fly
Theravance Biopharma options imply 3.2% move in share price post-earnings
3M ago
TBPH
Theravance Biopharma downgraded to Perform from Outperform at Oppenheimer
PremiumThe Fly
Theravance Biopharma downgraded to Perform from Outperform at Oppenheimer
3M ago
TBPH
Theravance Biopharma downgraded at Oppenheimer after ampreloxetine miss
PremiumThe Fly
Theravance Biopharma downgraded at Oppenheimer after ampreloxetine miss
3M ago
TBPH
Theravance Biopharma price target lowered to $15 from $27 at H.C. Wainwright
PremiumThe FlyTheravance Biopharma price target lowered to $15 from $27 at H.C. Wainwright
3M ago
TBPH
Theravance Biopharma downgraded to Neutral from Buy at B. Riley
Premium
The Fly
Theravance Biopharma downgraded to Neutral from Buy at B. Riley
3M ago
TBPH
Theravance Biopharma price target lowered to $21 from $40 at BTIG
Premium
The Fly
Theravance Biopharma price target lowered to $21 from $40 at BTIG
3M ago
TBPH
Midday Fly By: Target earnings hit the mark, Elliott invests $1B in Pinterest
PremiumThe Fly
Midday Fly By: Target earnings hit the mark, Elliott invests $1B in Pinterest
3M ago
CI
ZD
Theravance Biopharma falls 28% to $13.55 in pre-market trading
PremiumThe Fly
Theravance Biopharma falls 28% to $13.55 in pre-market trading
3M ago
TBPH
Theravance Biopharma implements cost reduction actions after study results
PremiumThe Fly
Theravance Biopharma implements cost reduction actions after study results
3M ago
TBPH
Theravance Biopharma Restructures After Ampreloxetine Trial Failure
PremiumCompany Announcements
Theravance Biopharma Restructures After Ampreloxetine Trial Failure
3M ago
8K
TBPH
Theravance Biopharma trading resumes
PremiumThe FlyTheravance Biopharma trading resumes
3M ago
TBPH
Theravance Biopharma says Phase 3 CYPRESS Study did not meet primary endpoint
Premium
The Fly
Theravance Biopharma says Phase 3 CYPRESS Study did not meet primary endpoint
3M ago
TBPH
Theravance Biopharma winding down ampreloxetine program after Phase 3 results
Premium
The Fly
Theravance Biopharma winding down ampreloxetine program after Phase 3 results
3M ago
TBPH

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >